Rischke H Christian, Beck Teresa, Vach Werner, Wieser Gesche, Grosu Anca L, Schultze-Seemann Wolfgang, Meyer Philipp T, Jilg Cordula A
Department of Radiation Oncology, University of Freiburg, Hugstetterstr 55, 79106, Freiburg, Germany,
Eur J Nucl Med Mol Imaging. 2014 Nov;41(11):2074-82. doi: 10.1007/s00259-014-2829-0. Epub 2014 Jun 21.
(18)F-Fluoroethylcholine ((18)F-FECh) is excreted via the urinary system with high activity accumulation in the urinary bladder. Furosemide and oral hydration can be administered concomitantly to reduce urinary activity to provide better detectability of retroperitoneal and pelvic lesions. Currently it is unknown if there is any effect of furosemide on (18)F-FECh uptake in organs, tissues and tumour lesions and the extent to which image quality along the urinary tract may be improved by furosemide.
We retrospectively analysed 217 (18)F-FECh PET/CT examinations from 213 patients with known prostate cancer (PCa), performed either with oral hydration (109) or furosemide 20 mg together with oral hydration (108). Maximum (18)F-FECh uptake in different organs, tissues, lymph nodes and osseous metastases was quantified in terms of standardized uptake value (SUV) in a volume of interest and compared between the two groups. To characterize the impact of furosemide on lesion detectability a three-point rating scale was used to assess the presence of focal activity spots in the ureters and of perivesicular artefacts.
Patient characteristics and distribution of tumour lesions were well balanced between the two groups. Overall, SUVmax values from normal organs were increased after furosemide compared to the values in patients scanned without furosemide. Significant changes were observed in the salivary glands, liver, spleen, pancreas, kidneys, gluteus muscle and perirenal fat. SUVmax values were significantly decreased after furosemide in lymph node metastases (SUVmax 4.81 ± 2.68 vs. 6.48 ± 4.22, p = 0.0006), but not in osseous metastases. Evaluation of image quality along the urinary tract revealed significantly better depiction of the perivesicular space and significantly less focal tracer accumulation in the ureters in patients receiving furosemide, but the number of detected lymph nodes was not significantly different.
Furosemide administration reduced choline uptake in tumour lesions, especially significant in pelvic lymph node metastases. Although furosemide administration improved image quality, optimal image quality may also be obtained by adequate hydration without the risk of diminishing choline uptake in PCa lesions. Therefore a controlled hydration protocol seems more appropriate than administration of furosemide.
(18)F - 氟乙基胆碱((18)F - FECh)通过泌尿系统排泄,在膀胱中有高活性积聚。可同时给予呋塞米和口服补液以降低尿液活性,从而更好地检测腹膜后和盆腔病变。目前尚不清楚呋塞米对(18)F - FECh在器官、组织和肿瘤病变中的摄取是否有任何影响,以及呋塞米可在多大程度上改善沿尿路的图像质量。
我们回顾性分析了213例已知前列腺癌(PCa)患者的217次(18)F - FECh PET/CT检查,其中109例仅进行口服补液,108例在口服补液的同时给予20 mg呋塞米。通过感兴趣体积内的标准化摄取值(SUV)对不同器官、组织、淋巴结和骨转移灶中的最大(18)F - FECh摄取进行定量,并在两组之间进行比较。为了表征呋塞米对病变检测能力的影响,使用三点评分量表评估输尿管中局灶性活性点和膀胱周围伪影的存在情况。
两组患者的特征和肿瘤病变分布均衡。总体而言,与未使用呋塞米扫描的患者相比,使用呋塞米后正常器官的SUVmax值有所增加。在唾液腺、肝脏、脾脏、胰腺、肾脏、臀大肌和肾周脂肪中观察到显著变化。呋塞米治疗后,淋巴结转移灶的SUVmax值显著降低(SUVmax 4.81±2.68 vs. 6.48±4.22,p = 0.0006),但骨转移灶中未降低。对尿路图像质量的评估显示,接受呋塞米治疗的患者膀胱周围间隙的显示明显更好,输尿管中局灶性示踪剂积聚明显减少,但检测到的淋巴结数量没有显著差异。
给予呋塞米可降低肿瘤病变中的胆碱摄取,在盆腔淋巴结转移中尤为显著。虽然给予呋塞米可改善图像质量,但通过充分补液也可获得最佳图像质量,且无降低PCa病变中胆碱摄取的风险。因此,控制补液方案似乎比给予呋塞米更合适。